Skip to main content

Main menu

  • Home
  • Content
    • Published Ahead of Print
    • Current Issue
    • JASN Podcasts
    • Article Collections
    • Archives
    • Kidney Week Abstracts
    • Saved Searches
  • Authors
    • Submit a Manuscript
    • Author Resources
  • Editorial Team
  • Editorial Fellowship
    • Editorial Fellowship Team
    • Editorial Fellowship Application Process
  • More
    • About JASN
    • Advertising
    • Alerts
    • Feedback
    • Impact Factor
    • Reprints
    • Subscriptions
  • ASN Kidney News
  • Other
    • ASN Publications
    • CJASN
    • Kidney360
    • Kidney News Online
    • American Society of Nephrology

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
American Society of Nephrology
  • Other
    • ASN Publications
    • CJASN
    • Kidney360
    • Kidney News Online
    • American Society of Nephrology
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Advertisement
American Society of Nephrology

Advanced Search

  • Home
  • Content
    • Published Ahead of Print
    • Current Issue
    • JASN Podcasts
    • Article Collections
    • Archives
    • Kidney Week Abstracts
    • Saved Searches
  • Authors
    • Submit a Manuscript
    • Author Resources
  • Editorial Team
  • Editorial Fellowship
    • Editorial Fellowship Team
    • Editorial Fellowship Application Process
  • More
    • About JASN
    • Advertising
    • Alerts
    • Feedback
    • Impact Factor
    • Reprints
    • Subscriptions
  • ASN Kidney News
  • Follow JASN on Twitter
  • Visit ASN on Facebook
  • Follow JASN on RSS
  • Community Forum

randomized controlled trials

  • You have accessRestricted Access
    Optimizing the Design and Analysis of Future AKI Trials
    Matthieu Legrand, Sean M. Bagshaw, Jay L. Koyner, Ivonne H. Schulman, Michael R. Mathis, Juliane Bernholz, Steven Coca, Martin Gallagher, Stéphane Gaudry, Kathleen D. Liu, Ravindra L. Mehta, Romain Pirracchio, Abigail Ryan, Dominik Steubl, Norman Stockbridge, Fredrik Erlandsson, Alparslan Turan, F. Perry Wilson, Alexander Zarbock, Michael P. Bokoch, Jonathan D. Casey, Patrick Rossignol and Michael O. Harhay
    JASN August 2022, 33 (8) 1459-1470; DOI: https://doi.org/10.1681/ASN.2021121605
    Add to Selected Citations
  • Albuminuria-Lowering Effect of Dapagliflozin, Eplerenone, and Their Combination in Patients with Chronic Kidney Disease: A Randomized Crossover Clinical Trial
    You have accessRestricted Access
    Albuminuria-Lowering Effect of Dapagliflozin, Eplerenone, and Their Combination in Patients with Chronic Kidney Disease: A Randomized Crossover Clinical Trial
    Michele Provenzano, Maria Jesús Puchades, Carlo Garofalo, Niels Jongs, Luis D’Marco, Michele Andreucci, Luca De Nicola, Jose Luis Gorriz and Hiddo J.L. Heerspink; on behalf of the ROTATE-3 study group
    JASN August 2022, 33 (8) 1569-1580; DOI: https://doi.org/10.1681/ASN.2022020207
    Add to Selected Citations
  • You have accessRestricted Access
    More Research is Still Needed To Support The Real-world Generalizability of The Benefits of Lifestyle Interventions for CKD
    Liuyan Huang and Fan Zhang
    JASN May 2022, 33 (5) 1045; DOI: https://doi.org/10.1681/ASN.2022020172
    Add to Selected Citations
  • You have accessRestricted Access
    Authors’ Reply: More Research is Still Needed to Support the Real-World Generalizability of the Benefits of Lifestyle Interventions for Chronic Kidney Disease
    Kassia S. Beetham, Jeff S. Coombes and Erin J. Howden
    JASN May 2022, 33 (5) 1045-1046; DOI: https://doi.org/10.1681/ASN.2022030244
    Add to Selected Citations
  • You have accessRestricted Access
    Plasma Exchange in ANCA-Associated Vasculitis: For Whom (If Any)?
    Michael Walsh
    JASN March 2022, 33 (3) 465-466; DOI: https://doi.org/10.1681/ASN.2021121550
    Add to Selected Citations
  • Acute Treatment Effects on GFR in Randomized Clinical Trials of Kidney Disease Progression
    You have accessRestricted Access
    Acute Treatment Effects on GFR in Randomized Clinical Trials of Kidney Disease Progression
    Brendon L. Neuen, Hocine Tighiouart, Hiddo J.L. Heerspink, Edward F. Vonesh, Juhi Chaudhari, Shiyuan Miao, Tak Mao Chan, Fernando C. Fervenza, Jürgen Floege, Marian Goicoechea, William G. Herrington, Enyu Imai, Tazeen H. Jafar, Julia B. Lewis, Philip Kam-Tao Li, Francesco Locatelli, Bart D. Maes, Ronald D. Perrone, Manuel Praga, Annalisa Perna, Francesco P. Schena, Christoph Wanner, Jack F.M. Wetzels, Mark Woodward, Di Xie, Tom Greene, Lesley A. Inker and on behalf of CKD-EPI Clinical Trials
    JASN February 2022, 33 (2) 291-303; DOI: https://doi.org/10.1681/ASN.2021070948
    Add to Selected Citations
  • Open Access
    Hyperkalemia Risk with Finerenone: Results from the FIDELIO-DKD Trial
    Rajiv Agarwal, Amer Joseph, Stefan D. Anker, Gerasimos Filippatos, Peter Rossing, Luis M. Ruilope, Bertram Pitt, Peter Kolkhof, Charlie Scott, Robert Lawatscheck, Daniel J. Wilson, George L. Bakris and on behalf of the FIDELIO-DKD Investigators
    JASN January 2022, 33 (1) 225-237; DOI: https://doi.org/10.1681/ASN.2021070942
    Add to Selected Citations
  • You have accessRestricted Access
    Effect of Low-Dose Methotrexate on eGFR and Kidney Adverse Events: A Randomized Clinical Trial
    Jeffrey A. Sparks, Kathleen M. M. Vanni, Matthew A. Sparks, Chang Xu, Leah M. Santacroce, Robert J. Glynn, Paul M. Ridker and Daniel H. Solomon
    JASN December 2021, 32 (12) 3197-3207; DOI: https://doi.org/10.1681/ASN.2021050598
    Add to Selected Citations
  • Conversion from Calcineurin Inhibitor– to Belatacept-Based Maintenance Immunosuppression in Renal Transplant Recipients: A Randomized Phase 3b Trial
    Open Access
    Conversion from Calcineurin Inhibitor– to Belatacept-Based Maintenance Immunosuppression in Renal Transplant Recipients: A Randomized Phase 3b Trial
    Klemens Budde, Rohini Prashar, Hermann Haller, Maria C. Rial, Nassim Kamar, Avinash Agarwal, Johan W. de Fijter, Lionel Rostaing, Stefan P. Berger, Arjang Djamali, Nicolae Leca, Lisa Allamassey, Sheng Gao, Martin Polinsky and Flavio Vincenti
    JASN December 2021, 32 (12) 3252-3264; DOI: https://doi.org/10.1681/ASN.2021050628
    Add to Selected Citations
  • Open Access
    Large Between-Patient Variability in eGFR Decline before Clinical Trial Enrollment and Impact on Atrasentan’s Efficacy: A Post Hoc Analysis from the SONAR Trial
    Simke W. Waijer, Sieta T. de Vries, Robert Busch, Di Xie, Ron T. Gansevoort, Fan Fan Hou, Jose L. Górriz, Gozewijn D. Laverman, Luca De Nicola, Julio Pascual, Michele Provenzano, Pablo E. Pergola, Sydney C.W. Tang, Christoph Wanner, Philippe Zaoui, Hans-Henrik Parving, Dick de Zeeuw and Hiddo J.L. Heerspink
    JASN November 2021, 32 (11) 2731-2734; DOI: https://doi.org/10.1681/ASN.2021040498
    Add to Selected Citations

Pages

  • Next
  • 1
  • 2
  • 3
  • 4

Articles

  • Current Issue
  • Early Access
  • Subject Collections
  • Article Archive
  • ASN Annual Meeting Abstracts

Information for Authors

  • Submit a Manuscript
  • Author Resources
  • Editorial Fellowship Program
  • ASN Journal Policies
  • Reuse/Reprint Policy

About

  • JASN
  • ASN
  • ASN Journals
  • ASN Kidney News

Journal Information

  • About JASN
  • JASN Email Alerts
  • JASN Key Impact Information
  • JASN Podcasts
  • JASN RSS Feeds
  • Editorial Board

More Information

  • Advertise
  • ASN Podcasts
  • ASN Publications
  • Become an ASN Member
  • Feedback
  • Follow on Twitter
  • Password/Email Address Changes
  • Subscribe to ASN Journals
  • Wolters Kluwer Partnership

© 2022 American Society of Nephrology

Print ISSN - 1046-6673 Online ISSN - 1533-3450

Powered by HighWire